Literature DB >> 25337754

Shortening treatment for tuberculosis--to basics.

Digby F Warner1, Valerie Mizrahi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25337754     DOI： 10.1056/NEJMe1410977

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  26 in total

1.  Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry.

Authors:  Jan-Willem C Alffenaar; Mathieu Bolhuis; Kai van Hateren; Marieke Sturkenboom; Onno Akkerman; Wiel de Lange; Ben Greijdanus; Tjip van der Werf; Daan Touw
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

Review 2.  A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Authors:  Anushka Naidoo; Kogieleum Naidoo; Helen McIlleron; Sabiha Essack; Nesri Padayatchi
Journal:  J Clin Pharmacol       Date:  2017-07-24       Impact factor: 3.126

Review 3.  Respiratory Infections in the U.S. Military: Recent Experience and Control.

Authors:  Jose L Sanchez; Michael J Cooper; Christopher A Myers; James F Cummings; Kelly G Vest; Kevin L Russell; Joyce L Sanchez; Michelle J Hiser; Charlotte A Gaydos
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

4.  Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.

Authors:  Si-Yang Li; Scott M Irwin; Paul J Converse; Khisi E Mdluli; Anne J Lenaerts; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

Review 5.  Inhibiting Mycobacterium tuberculosis within and without.

Authors:  Stewart T Cole
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-11-05       Impact factor: 6.237

6.  Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?

Authors:  Jean-Philippe Lanoix; Richard E Chaisson; Eric L Nuermberger
Journal:  Clin Infect Dis       Date:  2015-11-01       Impact factor: 9.079

Review 7.  Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.

Authors:  Lloyd Tanner; Paolo Denti; Lubbe Wiesner; Digby F Warner
Journal:  IUBMB Life       Date:  2018-06-22       Impact factor: 3.885

8.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

Review 9.  Profile of delamanid for the treatment of multidrug-resistant tuberculosis.

Authors:  John D Szumowski; John B Lynch
Journal:  Drug Des Devel Ther       Date:  2015-01-29       Impact factor: 4.162

10.  In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.

Authors:  Elsje Pienaar; Véronique Dartois; Jennifer J Linderman; Denise E Kirschner
Journal:  BMC Syst Biol       Date:  2015-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.